Literature DB >> 31978225

High total metabolic tumor volume at baseline predicts survival independent of response to therapy.

Laetitia Vercellino1, Anne-Segolene Cottereau2, Olivier Casasnovas3, Hervé Tilly4, Pierre Feugier5, Loic Chartier6, Christophe Fruchart7, Louise Roulin8, Lucie Oberic9, Gian Matteo Pica10, Vincent Ribrag11, Julie Abraham12, Marc Simon13, Hugo Gonzalez14, Reda Bouabdallah15, Olivier Fitoussi16, Catherine Sebban17, Armando López-Guillermo18, Laurence Sanhes19, Franck Morschhauser20, Judith Trotman21, Bernadette Corront22, Bachra Choufi23, Sylvia Snauwaert24, Pascal Godmer25, Josette Briere26, Gilles Salles27, Philippe Gaulard28, Michel Meignan29, Catherine Thieblemont30,31.   

Abstract

Early identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed to aid stratification to innovative treatment. Previous studies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts survival of DLBCL patients. We analyzed the prognostic impact of TMTV and prognostic indices in DLBCL patients, aged 60 to 80 years, from the phase 3 REMARC study that randomized responding patients to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) into maintenance lenalidomide or placebo. TMTV was computed on baseline positron emission tomography/computed tomography using the 41% maximum standardized uptake value method; the optimal TMTV cutoff for progression-free (PFS) and overall survival (OS) was determined and confirmed by a training validation method. There were 301 out of 650 evaluable patients, including 192 patients classified as germinal center B-cell-like (GCB)/non-GCB and MYC/BCL2 expressor. Median baseline TMTV was 238 cm3; optimal TMTV cutoff was 220 cm3. Patients with high vs low TMTV showed worse/higher Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2, stage III or IV disease, >1 extranodal site, elevated lactate dehydrogenase, International Prognostic Index (IPI) 3-5, and age-adjusted IPI 2-3. High vs low TMTV significantly impacted PFS and OS, independent of maintenance treatment. Although the GCB/non-GCB profile and MYC expression did not correlate with TMTV/survival, BCL2 >70% impacted PFS and could be stratified by TMTV. Multivariate analysis identified baseline TMTV and ECOG PS as independently associated with PFS and OS. Even in responding patients, after R-CHOP, high baseline TMTV was a strong prognosticator of inferior PFS and OS. Moreover, TMTV combined with ECOG PS may identify an ultra-risk DLBCL population. This trial was registered at www.clinicaltrials.gov as #NCT01122472.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31978225      PMCID: PMC7162688          DOI: 10.1182/blood.2019003526

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  Relapsed/refractory diffuse large B-cell lymphoma.

Authors:  Jonathan W Friedberg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Optimizing initial therapy in DLBCL.

Authors:  Catherine Thieblemont; Sophie Bernard; Michel Meignan; Thierry Molina
Journal:  Best Pract Res Clin Haematol       Date:  2018-08-07       Impact factor: 3.020

3.  Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

Authors:  Catherine Thieblemont; Hervé Tilly; Maria Gomes da Silva; Rene-Olivier Casasnovas; Christophe Fruchart; Franck Morschhauser; Corinne Haioun; Julien Lazarovici; Anida Grosicka; Aurore Perrot; Judith Trotman; Catherine Sebban; Dolores Caballero; Richard Greil; Koen van Eygen; Amos M Cohen; Hugo Gonzalez; Reda Bouabdallah; Lucie Oberic; Bernadette Corront; Bachra Choufi; Armando Lopez-Guillermo; John Catalano; Achiel Van Hoof; Josette Briere; Jose Cabeçadas; Gilles Salles; Philippe Gaulard; Andre Bosly; Bertrand Coiffier
Journal:  J Clin Oncol       Date:  2017-04-20       Impact factor: 44.544

Review 4.  Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

Authors:  Grzegorz S Nowakowski; Kristie A Blum; Brad S Kahl; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; David G Maloney; Laurie H Sehn; Michael E Williams; Wyndham H Wilson; John P Leonard; Sonali M Smith
Journal:  J Natl Cancer Inst       Date:  2016-12-16       Impact factor: 13.506

5.  18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome.

Authors:  Anne-Ségolène Cottereau; Christophe Nioche; Anne-Sophie Dirand; Jérôme Clerc; Franck Morschhauser; Olivier Casasnovas; Michel Meignan; Irène Buvat
Journal:  J Nucl Med       Date:  2019-06-14       Impact factor: 10.057

6.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

7.  Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden.

Authors:  Sally F Barrington; Michel Meignan
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

8.  Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.

Authors:  Anne-Ségolène Cottereau; Hélène Lanic; Sylvain Mareschal; Michel Meignan; Pierre Vera; Hervé Tilly; Fabrice Jardin; Stéphanie Becker
Journal:  Clin Cancer Res       Date:  2016-03-02       Impact factor: 12.531

9.  An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.

Authors:  Zheng Zhou; Laurie H Sehn; Alfred W Rademaker; Leo I Gordon; Ann S Lacasce; Allison Crosby-Thompson; Ann Vanderplas; Andrew D Zelenetz; Gregory A Abel; Maria A Rodriguez; Auayporn Nademanee; Mark S Kaminski; Myron S Czuczman; Michael Millenson; Joyce Niland; Randy D Gascoyne; Joseph M Connors; Jonathan W Friedberg; Jane N Winter
Journal:  Blood       Date:  2013-11-21       Impact factor: 22.113

Review 10.  How I manage patients with relapsed/refractory diffuse large B cell lymphoma.

Authors:  Christian Gisselbrecht; Eric Van Den Neste
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

View more
  23 in total

1.  Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Authors:  Laetitia Vercellino; Roberta Di Blasi; Salim Kanoun; Benoit Tessoulin; Cedric Rossi; Maud D'Aveni-Piney; Lucie Obéric; Caroline Bodet-Milin; Pierre Bories; Pierre Olivier; Ingrid Lafon; Alina Berriolo-Riedinger; Eugenio Galli; Sophie Bernard; Marie-Thérèse Rubio; Celine Bossard; Veronique Meignin; Pascal Merlet; Pierre Feugier; Steven Le Gouill; Loic Ysebaert; Olivier Casasnovas; Michel Meignan; Sylvie Chevret; Catherine Thieblemont
Journal:  Blood Adv       Date:  2020-11-24

Review 2.  Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions).

Authors:  Navid Hasani; Sriram S Paravastu; Faraz Farhadi; Fereshteh Yousefirizi; Michael A Morris; Arman Rahmim; Mark Roschewski; Ronald M Summers; Babak Saboury
Journal:  PET Clin       Date:  2022-01

Review 3.  CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure.

Authors:  Ana Carolina Caballero; Laura Escribà-Garcia; Carmen Alvarez-Fernández; Javier Briones
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

4.  Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters.

Authors:  Zsombor Ritter; László Papp; Katalin Zámbó; Zoltán Tóth; Dániel Dezső; Dániel Sándor Veres; Domokos Máthé; Ferenc Budán; Éva Karádi; Anett Balikó; László Pajor; Árpád Szomor; Erzsébet Schmidt; Hussain Alizadeh
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

5.  Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.

Authors:  Lale Kostakoglu; Federico Mattiello; Maurizio Martelli; Laurie H Sehn; David Belada; Chiara Ghiggi; Neil Chua; Eva González-Barca; Xiaonan Hong; Antonio Pinto; Yuankai Shi; Yoichi Tatsumi; Christopher Bolen; Andrea Knapp; Gila Sellam; Tina Nielsen; Deniz Sahin; Umberto Vitolo; Marek Trněný
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

6.  Intraperitoneal Glucose Transport to Micrometastasis: A Multimodal In Vivo Imaging Investigation in a Mouse Lymphoma Model.

Authors:  Zsombor Ritter; Katalin Zámbó; Xinkai Jia; Dávid Szöllősi; Dániel Dezső; Hussain Alizadeh; Ildikó Horváth; Nikolett Hegedűs; David Tuch; Kunal Vyas; Péter Balogh; Domokos Máthé; Erzsébet Schmidt
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

7.  Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.

Authors:  N George Mikhaeel; Martijn W Heymans; Jakoba J Eertink; Henrica C W de Vet; Ronald Boellaard; Ulrich Dührsen; Luca Ceriani; Christine Schmitz; Sanne E Wiegers; Andreas Hüttmann; Pieternella J Lugtenburg; Emanuele Zucca; Gerben J C Zwezerijnen; Otto S Hoekstra; Josée M Zijlstra; Sally F Barrington
Journal:  J Clin Oncol       Date:  2022-03-31       Impact factor: 50.717

8.  Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy.

Authors:  Ajlan Al Zaki; Lei Feng; Grace Watson; Sairah A Ahmed; Haleigh Mistry; Loretta J Nastoupil; Misha Hawkins; Ranjit Nair; Swaminathan P Iyer; Hun J Lee; Raphael E Steiner; Christopher R Flowers; Elizabeth J Shpall; Partow Kebriaei; Sattva S Neelapu; Jason R Westin; Paolo Strati
Journal:  Blood Adv       Date:  2022-05-10

9.  Value of total lesion glycolysis and cell-of-origin subtypes for prognostic stratification of diffuse large B-cell lymphoma patients.

Authors:  Chong Jiang; Yue Teng; Zhong Zheng; Zhengyang Zhou; Jingyan Xu
Journal:  Quant Imaging Med Surg       Date:  2021-06

10.  Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review.

Authors:  Simone Krebs; Julia G Barasch; Robert J Young; Christian Grommes; Heiko Schöder
Journal:  Ann Lymphoma       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.